Monitoring of Outcomes of Cellular and Exosome-based Therapies in Autoinflammatory and Post-infectious Neuroinflammatory Syndromes

Biocells Medical

Status: Active, not recruiting

Conditions: Early-stage Panencephalitis; Neuroinflammatory Demyelination; Autoimmune Encephalitis

Treatments: Biological: Allogeneic MSC infusions (IV)

Study type: Observational

Funder types: Industry

Identifiers

NCT07145502

Bio120001

Details and patient eligibility

About

This is a prospective, non-randomized, observational registry study evaluating the clinical outcomes of patients with autoimmune or post-infectious neuroinflammatory syndromes receiving stem cell-derived biologics (including mesenchymal stem cells and exosomes) at Biocells Medical clinics. The study aims to track improvements in neurological function, inflammatory biomarkers, and patient-reported quality of life following individualized regenerative interventions.

Enrollment: 76 patients

Sex: All

Ages: 6 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• • Age 6-70

  • Diagnosis of one of the eligible syndromes by neurologist or immunologist
  • Unresponsive or partially responsive to conventional therapy
  • Informed consent provided

Exclusion criteria

• • Active malignancy

  • Severe systemic infection
  • Contraindications to IV biologics

Trial design

76 participants in 1 patient group

B1

Description:

* Age 6-70 * Diagnosis of one of the eligible syndromes by neurologist or immunologist * Unresponsive or partially responsive to conventional therapy * Informed consent provided

Treatment:

Biological: Allogeneic MSC infusions (IV)